The new results show that HIV-infected patients who received TNX-355 maintained a considerably greater reduction in viral load than patients given placebo in combination with an optimized background regimen.
The 48-week results also showed that patients who received TNX-355 in combination with the background regimen experienced a statistically significant increase in CD4+ cells compared to those who received placebo plus the background regimen.
“The 48-week results demonstrate the ability of TNX-355 to produce durable viral-load suppression, while also providing a clinically meaningful immunologic response,” said Danong Chen, Tanox president and CEO. “These data suggest that TNX-355 has the potential to be a first-in-class therapy to advance HIV care for treatment-experienced patients.”